Biotech · Private company
Akamis Bio
Track this companyFree. Adds Akamis Bio to your Dealase workspace and tells you when its record changes.
Clinical trials71 recruiting or active
Pipeline programs9From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline9
- Capecitabine oral administrationPhase 1 · Locally Advanced Rectal Cancer (LARC)ClinicalTrials.gov · fetched Nov 12, 2026
- enadenotucirevPhase 1 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- NG-350APhase 1 · Metastatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- NG-350A IV administrationPhase 1 · Locally Advanced Rectal Cancer (LARC)ClinicalTrials.gov · fetched Nov 12, 2026
- NG-350A plus PembrolizumabPhase 1 · Epithelial TumorClinicalTrials.gov · fetched Nov 12, 2026
- NG-641Phase 1 · Metastatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- NG-641 in combination with NivolumabPhase 1 · Metastatic CancerClinicalTrials.gov · fetched Nov 12, 2026
- nivolumabPhase 1 · Colorectal CancerClinicalTrials.gov · fetched Nov 12, 2026
- RadiotherapyPhase 1 · Locally Advanced Rectal Cancer (LARC)ClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials7
- NG-350A Plus Chemoradiotherapy for Locally Advanced Rectal CancerPHASE1 · ACTIVE_NOT_RECRUITING · started Apr 7, 2025ClinicalTrials.gov NCT06459869 · fetched Nov 12, 2026
- Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)PHASE1 · COMPLETED · started Apr 13, 2022ClinicalTrials.gov NCT05165433 · fetched Nov 12, 2026
- Study of NG-641 in Combination With Nivolumab in Metastatic or Advanced Epithelial TumoursPHASE1 · COMPLETED · started Dec 1, 2021ClinicalTrials.gov NCT05043714 · fetched Nov 12, 2026
- Exploratory Platform Trial to Evaluate Immunotherapy Combinations With Chemotherapy for the Treatment of Patients With Previously Untreated Metastatic Pancreatic AdenocarcinomaPHASE1 · COMPLETED · started Aug 9, 2021ClinicalTrials.gov NCT04787991 · fetched Nov 12, 2026
- First in Human Study With NG-641, a Tumour Selective Transgene Expressing Adenoviral VectorPHASE1 · COMPLETED · started Jan 23, 2020ClinicalTrials.gov NCT04053283 · fetched Nov 12, 2026
- First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)PHASE1 · COMPLETED · started Feb 19, 2019ClinicalTrials.gov NCT03852511 · fetched Nov 12, 2026
- Phase I Study of Enadenotucirev and PD-1 Inhibitor in Subjects With Metastatic or Advanced Epithelial TumorsPHASE1 · COMPLETED · started Jan 25, 2016ClinicalTrials.gov NCT02636036 · fetched Nov 12, 2026